SecurityPFNX / Pfenex Inc. (717071104)
IndustryPharmaceutical Preparations
Institutional Owners57
Institutional Shares18,140,870 - 76.92%
Common Shares Outstanding23,583,585 shares (as of 2018-03-31)
Institutional Value$ 113,403,000 USD

Institutional Stock Ownership and Shareholders()

Pfenex Inc. (AMEX:PFNX) has 57 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 18,140,870 shares. Largest shareholders include Franklin Resources Inc, Primecap Management Co/ca/, Dow Chemical Co /de/, Deerfield Management Co, Blair William & Co/il, Renaissance Technologies LLC, Sanders Morris Harris Inc., BlackRock Advisors LLC, Vanguard Group Inc, and BlackRock Fund Advisors.
Pfenex Inc. (AMEX:PFNX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR Marshall Wace North America L.P. 292,483 292,483 0.00 778 1,755 125.58
2017-11-09 13F-HR TFS CAPITAL LLC 60,894 0 -100.00 244 0 -100.00
2018-05-11 13F-HR GSA CAPITAL PARTNERS LLP 11,248 11,248 0.00 30 67 123.33
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 348,848 350,211 0.39 3,122 3,176 1.73
2018-05-15 13F-HR Bank of New York Mellon Corp 24,534 28,215 15.00 65 170 161.54
2018-05-15 13F-HR UBS Group AG 17 17 0.00 0 0
2018-05-10 13F-HR Spark Investment Management LLC 69,100 64,100 -7.24 183 384 109.84
2018-05-11 13F-HR MACQUARIE GROUP LTD 9,748 6,648 -31.80 26 40 53.85
2018-05-15 13F-HR ELEMENT CAPITAL MANAGEMENT LLC 0 10,506 0 63
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 1,598 871 -45.49 4 5 25.00
2018-05-14 13F-HR Renaissance Technologies LLC 1,010,600 1,098,800 8.73 2,688 6,593 145.28
2018-04-27 13F-HR Chicago Partners Investment Group LLC 2,500 2,500 0.00 7 15 114.29
2018-07-09 13F-HR Fisher Asset Management, LLC 122,147 0 -100.00 733 0 -100.00
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 108,500 108,500 0.00 289 651 125.26
2017-08-14 13F-HR NUMERIC INVESTORS LLC 281,392 186,608 -33.68 1,635 748 -54.25
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 0 54,116 0 325
2018-05-03 13F-HR Zurcher Kantonalbank (Zurich Cantonalbank) 21,400 15,400 -28.04 57 92 61.40
2017-08-14 13F-HR I.G. INVESTMENT MANAGEMENT, LTD. 0 225,000 0 902
2018-05-09 13F-HR FEDERATED INVESTORS INC /PA/ 624 4
2017-02-10 13F-HR BlackRock Group LTD 285,831 280,292 -1.94 2,558 2,542 -0.63
2018-05-08 13F-HR Phoenix Investment Adviser LLC 7,000 7,000 0.00 19 42 121.05
2018-05-07 13F-HR MUFG Americas Holdings Corp 390 0 -100.00 1 0 -100.00
2018-05-03 13F-HR CAM Group Holding A/S 250,300 201,274 -19.59 666 1,208 81.38
2018-05-15 13F-HR BARCLAYS PLC 0 1 0 0
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 92,251 86,816 -5.89 245 520 112.24
2017-02-10 13F-HR BlackRock Advisors LLC 763,819 769,213 0.71 6,836 6,977 2.06
2018-05-15 13F-HR RBF Capital, LLC 15,456 15,456 0.00 41 82 100.00
2018-04-26 13F-HR WESTWOOD MANAGEMENT CORP /IL/ 32,000 192
2018-05-14 13F-HR Connor, Clark & Lunn Investment Management Ltd. 32,345 32,345 0.00 86 194 125.58
2018-05-15 13F-HR DEERFIELD MANAGEMENT CO 830,216 1,659,501 99.89 2,208 9,957 350.95
2018-05-15 13F-HR PERCEPTIVE ADVISORS LLC 519,773 0 -100.00 1,383 0 -100.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 332,060 233,025 -29.82 883 1,398 58.32
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 4 0 -100.00 0 0
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 97,565 99,215 1.69 260 595 128.85
2018-05-15 13F-HR JACOBS LEVY EQUITY MANAGEMENT, INC 85,332 36,192 -57.59 227 217 -4.41
2018-05-14 13F-HR MORGAN STANLEY 51,142 22,657 -55.70 136 136 0.00
2018-05-15 13F-HR STATE STREET CORP 11,200 11,200 0.00 30 67 123.33
2018-02-14 13F-HR NUMERIC INVESTORS LLC 272,339 193,852 -28.82 822 516 -37.23
2017-02-10 13F-HR BlackRock Fund Advisors 501,682 592,638 18.13 4,490 5,375 19.71
2018-05-15 13F-HR Man Group plc 128,554 771
2018-05-09 13F-HR NORTHERN TRUST CORP 38,584 41,935 8.68 103 252 144.66
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 24,199 24,199 0.00 64 145 126.56
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 14,000 84
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 55 51 -7.27 0 0
2018-05-15 13F-HR Squarepoint Ops LLC 45,673 0 -100.00 121 0 -100.00
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 5 5 0.00 13 30 130.77
2018-05-15 13F-HR BLAIR WILLIAM & CO/IL 851,248 1,369,920 60.93 2,264 8,220 263.07
2018-05-10 13F-HR FRANKLIN RESOURCES INC 2,783,060 2,776,155 -0.25 7,403 16,657 125.00
2017-10-31 13F-HR Nine Chapters Capital Management LLC 30,300 32,900 8.58 122 99 -18.85
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 49,155 34,713 -29.38 131 208 58.78
2018-05-15 13F-HR BlueCrest Capital Management Ltd 12,916 77
2018-05-04 13F-HR DOW CHEMICAL CO /DE/ 1,771,428 1,771,428 0.00 4,712 10,629 125.57
2018-07-10 13F-HR SANDERS MORRIS HARRIS INC. 973,674 877,935 -9.83 5,842 4,750 -18.69
2017-02-10 13F-HR BlackRock Investment Management, LLC 160,935 163,618 1.67 1,440 1,484 3.06
2018-05-14 13F-HR Commonwealth Equity Services, Llc. 97,465 584
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 341,869 451,311 32.01 909 2,708 197.91
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 359,288 104,937 -70.79 956 630 -34.10
2018-05-14 13F-HR PRIMECAP MANAGEMENT CO/CA/ 2,356,400 2,356,400 0.00 6,268 14,138 125.56
2018-05-15 13F-HR VANGUARD GROUP INC 667,444 717,814 7.55 1,775 4,307 142.65
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 65,000 65,000 0.00 173 390 125.43
2018-05-09 13F-HR BlackRock Inc. 453,669 368,771 -18.71 1,207 2,212 83.26
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 0 152 0 1
2018-05-10 13F-HR JP Morgan Chase & Co 155 14,301 9,126.45 0 86
2018-05-17 13F-HR Atlantic Trust Group, LLC 10,000 0 -100.00 27 0 -100.00
2017-02-10 13F-HR BlackRock Japan Co. Ltd 1,621 1,866 15.11 15 17 13.33

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up

2018-06-13 seekingalpha
Tetraphase Pharma (TTPH) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; they also have a Qualified Infectious Disease Product (‘QIDP) for the drug candidate. (478-4)

Your Daily Pharma Scoop: Recent IPO And Offerings Review

2018-05-31 seekingalpha
While we generally do not espouse IPO investing, this is a good place to start tracking interesting stocks early on. (104-9)

Pfenex: A Buy For Their Therapeutic Proteins Platform

2018-05-18 seekingalpha
On May 14, Pfenex announced positive topline results from a phase 3 trial which showed their lead candidate, PF708-301 had comparable overall profiles with Eli Lilly's Forteo in osteoporosis. (3-0)

Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments

2018-05-15 seekingalpha
Chiasma was able to get the FDA to favorably modify certain endpoints of its SPA-enabled trial. (85-3)

CUSIP: 717071104